Advancing Cancer Research Through Next Generation Sequencing at Mays Cancer Center of UT Health San Antonio

圣安东尼奥 UT Health 梅斯癌症中心通过下一代测序推进癌症研究

• 批准号: 10517546
• 负责人: Zhao Lai
• 金额: $ 19.14万
• 依托单位: UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-01 至 2027-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10517546
• 关键词: Advanced Malignant Neoplasm; Area; Award; Biological Assay; Cancer Center; Cancer Center Support Grant; Caring; Catchment Area; Collaborations; Communities; Core Facility; Custom; Development; Environment; Experimental Designs; Funding; Genomics; Grant; Health; High-Throughput Nucleotide Sequencing; Hispanic Populations; Infrastructure; Journals; Knowledge; Lead; Leadership; Letters; Malignant Childhood Neoplasm; Malignant Neoplasms; Methodology; Mission; Peer Review; Procedures; Protocols documentation; Publications; Research; Research Personnel; Research Project Grants; Research Project Summaries; Resource Sharing; Scientist; Secure; Services; Specialist; Strategic Planning; Supervision; Technology; Technology Assessment; Texas; Training; Training and Education; United States National Institutes of Health; Universities; anticancer research; base; cancer genome; cancer genomics; career development; innovation; instrumentation; member; next generation sequencing; programs; recruit; success; technology validation

Project Summary This Research Specialist (Core-based Scientist) R50 application seeks support for Dr. Zhao Lai, Director of the Next-Generation Sequencing Shared Resource (NGSSR) in the NCI-designated Mays Cancer Center (MCC; Ruben Mesa, PI) at the University of Texas Health San Antonio (UTHSA). Next-generation sequencing (NGS) is one of the most significant technological advances in cancer genome research. Dr. Lai’s mission through the NGSSR is to provide the cutting-edge genomics technology to the cancer community of MCC. The NGSSR began in 2011 as a core facility with a focus on genomics of pediatric cancer research. Dr. Lai was recruited as a highly qualified genomics scientist to lead the NGS facility. In 2014, the core was integrated into the Cancer Center Support Grant (CCSG) as a Shared Resource. As the NGSSR Director since its inception, Dr. Lai has guided the development of every aspect of this highly regarded Shared Resource (scored “Outstanding” in the successful CCSG renewal in 2020). She has developed and executed strategic plans for technology assessment and implementation, trained and supervised staff scientists, and created all standard operating procedures. Dr. Lai has secured two NIH S10 Shared Instrumentation grants to significantly enhance the genomic infrastructure at UTHSA, continuously established new protocols to expand NGS services to support diverse cancer research applications. She continues to assist investigators NGS projects ranging from experimental design through subsequent interpretation of experimental results, and establishes the extensive collaboration to develop integrative assays and customized protocols that contribute to the long-term success of the MCC’s research program. Under her scientific leadership, the NGSSR has quickly become an essential component in the MCC and fundamentally transformed the genomics research environment for its members. Since 2011, the NGSSR’s Cancer Center users have nearly quadrupled. Currently, the NGSSR supports >42 Cancer Center members and 18 NCI-funded research projects. Dr. Lai’s knowledge of NGS technology and her key intellectual contribution to NGS applications in many NCI-funded research projects have been widely recognized (see Letters of Support), with the NGSSR’s contributions to over 100 publications, many in high-impact peer-reviewed journals. This proposed R50 award will provide a more stable financial basis for the NGS facility, further concentrate Dr. Lai’s efforts on cancer-oriented methodology development, application innovation, and service improvement, and offer her more opportunities in career development in cancer genomics. This award will also allow the NGSSR to continue providing cutting-edge sequencing technology, services, education, and training to MCC cancer research community to provide better care for the unique Hispanic population in our catchment area.

项目摘要 这位研究专家（基于核心的科学家）R50应用程序为Zhao Lai博士提供支持， NCI指定的MAYS癌症中心（MCC; 德克萨斯大学圣安东尼奥分校（UTHSA）的鲁本·梅萨（Ruben Mesa）。下一代测序（NGS） 是癌症基因组研究中最重要的技术进步之一。莱博士通过 NGSSR将为MCC的癌症社区提供尖端的基因组技术。 NGSSR 从2011年开始，作为核心设施，重点关注小儿癌症研究的基因组学。莱博士被招募为 一位高素质的基因组学科学家领导NGS设施。 2014年，核心被整合到癌症中 中心支持赠款（CCSG）作为共享资源。自成立以来，作为NGSSR主任，莱博士有 指导了这个备受推崇的共享资源的各个方面的发展（在 成功的CCSG在2020年更新）。她制定并执行了技术评估的战略计划 和实施，受过训练和监督的员工科学家，并创建了所有标准的操作程序。博士 LAI获得了两项NIH S10共享仪器赠款，以显着增强基因组基础设施 在UTHSA，不断建立了新的协议，以扩展NGS服务以支持潜水癌症研究 申请。她继续协助调查人员NGS项目，从实验设计到 随后对实验结果的解释，并建立了广泛的合作以发展 综合测定和定制协议有助于MCC研究的长期成功 程序。在她的科学领导下，NGSSR迅速成为MCC的重要组成部分 并从根本上改变了其成员的基因组研究环境。自2011年以来，NGSSR 癌症中心的使用者几乎三倍。目前，NGSSR支持> 42个癌症中心成员， 18 NCI资助的研究项目。莱博士对NGS技术的了解及其对 许多NCI资助的研究项目中的NGS应用已被广泛认可（请参阅支持信）， NGSSR对100多个出版物的贡献，许多在同行评审期刊上。这 拟议的R50奖将为NGS设施提供更稳定的财务基础，进一步集中于Lai博士 在面向癌症的方法论开发，应用创新和服务改进方面的努力，并提供 她在癌症基因组学方面的职业发展机会更多。该奖项还将允许NGSSR 继续为MCC癌症提供尖端的测序技术，服务，教育和培训 研究社区为我们的集水区中独特的西班牙裔人口提供更好的护理。